1. The use of a pharmaceutical composition containing at least one compound, which is either an agonist of two or more serotonin receptors selected from the group of receptors-5-HT 1B, -5-HT 1D, -5-HT 1F, or a selective agonist 5 -HT 1D receptor, or a selective 5-HT 1F receptor agonist, or a pharmaceutically acceptable derivative thereof, wherein the composition further comprises a 5-HT 1A receptor agonist or a pharmaceutically acceptable derivative thereof, for treating, preventing or alleviating the manifestation of motor disorders Food. 2. The use according to claim 1, wherein said compound has a higher affinity and / or receptor activation efficiency for the 5-HT 1D receptor compared to the 5-HT 1B receptor. The use according to claim 1, wherein the compound is a triptan or a pharmaceutically acceptable compound thereof. The use according to claim 1, wherein said compound is selected from the group consisting of sumatriptan, zolmitriptan, risatriptan, naratriptan, almotriptan, frovatriptan and eletriptan or their pharmaceutically acceptable derivatives. The use according to claim 1, wherein said compound is administered in doses of 0.05-200 mg / day. The use according to claim 1, wherein said compound is administered in doses of 0.5-60 mg / day, for example, in doses of 0.5-10 mg / day. The use according to claim 1, wherein said compound is administered in single doses of 0.05-100 mg / kg of patient weight. The use according to claim 1, wherein the 5-HT 1A receptor agonist is selected from the group consisting of alnespiron, binospiron, buspirone, hepiron, ipsapiron, perospiron, tandospiron, befradol, repinotan, piclozotan, osemozolan, flesinoxane, fliban�1. Применение фармацевтической композиции, содержащей по меньшей мере одно соединение, которое представляет собой или агонист двух или более серотониновых рецепторов, выбранных из группы рецепторов-5-НТ 1В,-5-HT 1D,-5-HT 1F,или селективный агонист 5-НТ 1D-рецептора, или селективный агонист 5-НТ 1F-рецептора, ил
